TABLE 3.

Subgroup analyses and results of meta‐regression models

Outcome			No. of studies	SRR	Lower 95% CI	Upper 95% CI	p‐value
OS	pT	T1–T2 only	6	0.97	0.87	1.45	0.60
		Any pT	22	1.13	0.85	1.49
	pN	N0 only	5	1.32	0.85	2.06	0.37
		Any pN	23	1.03	0.78	1.37
	Region	Europe	6	1.45	0.77	2.75	0.03
		USA/Australia	12	1.69	1.55	1.84
		East Asia	9	0.88	0.65	1.20
		Middle East	4	0.57	0.75	1.17
DSS	pT	T1–T2 only	6	0.97	0.65	1.45	0.69
		Any pT	13	0.81	0.50	1.18
	pN	N0 only	4	1.12	0.72	1.74	0.31
		Any pN	15	0.75	0.47	1.21
	Region	Europe	5	1.41	0.67	2.96	0.09
		USA/Australia	5	1.64	1.08	2.48
		East Asia	7	0.78	0.55	1.09
		Middle East	4	0.44	0.46	1.18
DFS	pT	T1–T2 only	0	‐	‐	‐
		Any pT	11	0.76	0.60	0.95	‐
	pN	N0 only	0	‐	‐	‐
		Any pN	11	0.76	0.60	0.95	‐
	Region	Europe	1	0.53	0.35	0.84	0.14
		USA/Australia	6	0.93	0.75	1.15
		East Asia	2	0.64	0.25	1.65
		Middle East	2	0.56	0.31	1.02
Local RFS	pT	T1–T2 only	4	0.96	0.70	1.31	0.06
		Any pT	10	0.67	0.52	0.84
	pN	N0 only	3	0.94	0.64	1.38	0.21
		Any pN	11	0.71	0.57	0.88
	Region	Europe	1	0.61	0.37	1.02	0.15
		USA/Australia	5	0.58	0.34	0.98
		East Asia	6	0.93	0.68	1.28
		Middle East	2	1.01	0.61	1.69
Regional RFS	pT	T1–T2 only	2	0.79	0.58	1.06	0.74
		Any pT	10	0.72	0.41	1.25
	pN	N0 only	2	0.79	0.58	1.06	0.74
		Any pN	10	0.72	0.41	1.25
	Region	Europe	1	0.96	0.53	1.75	0.57
		USA/Australia	5	0.51	0.24	1.08
		East Asia	5	0.94	0.44	2.01
		Middle East	1	1.93	0.28	13.35
Distant RFS	pT	T1–T2 only	1	0.16	0.06	0.42	0.21
		Any pT	11	0.73	0.32	1.67
	pN	N0 only	1	0.16	0.06	0.42	0.21
		Any pN	11	0.73	0.32	1.67
	Region	Europe	1	0.25	0.05	1.31	0.13
		USA/Australia	5	1.01	0.50	2.04
		East Asia	4	1.33	0.23	7.78
		Middle East	2	0.08	0.02	0.35

P‐value from meta‐regression for differences between subgroups

SRR, summary risk estimate; CI, confidence interval; OS, overall survival; DSS, disease‐specific survival; DFS, disease‐free survival; RFS, recurrence‐free survival; pT, pathological tumor; pN, pathological node.

SRR was estimated for older patients vs. younger patients.